On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdayAug 10, 2017 2:58 pm

NetworkNewsBreaks – Invictus MD Strategies Corp. (OTC: IVITF) (TSX-V: IMH) Provides Update on Harvesting

Invictus MD Strategies Corp. (OTC: IVITF) (TSX-V: IMH) today announced the completion of its wholly owned subsidiary’s first two harvests earlier this month. Both harvests exceeded expectations and two more harvests are expected the first week of September. Additionally, the company reported that the 27,800 sq. ft. production facility currently under construction is scheduled for completion by the end of January 2018. The additional space is projected to increase production by 800%. Dan Kriznic, Chairman & CEO, Invictus MD, commented, "Invictus MD is well capitalized for expansion with approximately $28.5 million in cash and is prepared for an exciting year of…

Continue Reading

ThursdayAug 10, 2017 12:08 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 10, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CYAN 24.46% – News: Posts fiscal Q1 2018 financial results LUNA 16.53% – News: Posts Q2, first half 2017 financial results IDND 11.11% – News: Qiagen utilizes The Answer® to dispense nuclease-free water for molecular testing RADA 9.79% – News: Posts Q2 2017 financial results, hosts conference call TRCK 7.14% – News: Posts fiscal Q3 2017 financial results MACE 6.20% – News: Posts Q2, first half 2017 unaudited financial results DYSL 5.78% – News:…

Continue Reading

ThursdayAug 10, 2017 9:53 am

NetworkNewsBreaks – Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Bioceres’ Joint Venture Receives Completed Safety Review by FDA

Arcadia Biosciences (NASDAQ: RKDA) before the bell said its joint venture with Bioceres S.A., Verdeca, has received notification that the FDA has completed its full review of the company’s safety evaluation for HB4 soybeans. This permits Verdeca products derived from HB4 soybeans to be used commercially in human food and animal feed. Additionally, completion of the FDA’s review marks a key regulatory achievement in the approval process for Verdeca’s HB4 drought stress tolerance trait. The company has submitted an environmental safety data petition to the U.S. Department of Agriculture (USDA) which is currently under review. The USDA is expected to…

Continue Reading

ThursdayAug 10, 2017 9:49 am

NetworkNewsBreaks – Data and Safety Monitoring Board Recommends Completion of ARCA biopharma, Inc.’s (NASDAQ: ABIO) GENETIC-AF Trial

ARCA biopharma (NASDAQ: ABIO) this morning said the GENETIC-AF trial Data and Safety Monitoring Board (DSMB) has completed its pre-specified phase 2B interim analysis and has recommended completion of the study with no changes to the trial design. GENETIC-AF is a clinical trial evaluating Gencaro™ as a candidate for the treatment of atrial fibrillation (AF). The Gencaro development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). “The DSMB stated that there were no safety concerns and that the efficacy results met the prespecified criteria for continuing the Phase 2B trial to completion. We…

Continue Reading

ThursdayAug 10, 2017 9:46 am

NetworkNewsBreaks – SeeThruEquity Issues Update, New PT on IEG Holdings Corp. (IEGH)

SeeThruEquity has updated its coverage and issued a new price target of $5.20 on shares of IEG Holdings Corp.’s (OTCQB: IEGH) stock following the company’s recent release of financial results for the second quarter of 2017. Among other highlights, the analyst noted that the results showed a decrease in operating costs as well as an improved balance sheet for IEG. Additionally, the company declared a cash dividend of $0.005 per common share for the second quarter of 2017. The dividend is payable on August 21, 2017, to stockholders of record at the close of business on Friday, August 11, 2017.…

Continue Reading

ThursdayAug 10, 2017 9:32 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the…

Continue Reading

WednesdayAug 09, 2017 12:44 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 9, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: RHNO 19.82% – News: Posts Q2 2017 financial results CNXR 13.98% – News: Releases results of consumer survey regarding health insurance CUI 13.27% – News: Posts unaudited Q2 2017 financial results BONL 12.36% – News: Posts fiscal Q1 2018 profits EFOI 10.99% – News: Posts Q2 2017 financial results VCEL 10.00% – News: Posts Q2 2017 financial results NIHD 9.16% – News: Posts Q2 2017 financial results PNAT 8.93% – News: Launches Pura Pro…

Continue Reading

WednesdayAug 09, 2017 12:40 pm

NetworkNewsBreaks – IPO Complete, China Internet Nationwide Financial Services, Inc. (NASDAQ: CIFS) Focuses on Providing Financial Solutions to Target Market in China

China Internet Nationwide Financial Services (NASDAQ: CIFS), on its second day as a NASDAQ-listed company, is trading at $11.93 on volume of just over 70,000. The provider of financial advisory services to the underserved small-to-medium sized enterprises in China yesterday ended its first day of trading up 23% at $12.30 per share. Boustead Securities, LLC served as the company’s lead underwriter and completed its IPO of 2,023,146 of CIFS’s ordinary shares priced at $10 per share for a total of $20,231,460 before underwriting discounts, commissions and offering expenses. "We are honored and humbled to become an official member of the…

Continue Reading

WednesdayAug 09, 2017 12:34 pm

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Close $50M in Second Tranche Equity Financing; Shares Fall

Amyris (NASDAQ: AMRS) is trading at a new 52-week low of $2.54, down more than 8% after reporting the close of the second and final tranche of its previously announced financing. The second tranche of a private placement resulted in a total of $50 million, comprised of a $25-million investment from Koninklijke DSM N.V. and $25 million contributed by Vivo Capital. “We’ve delivered a very strong first half and are on track for our best year ever with more than doubling our product sales and continuing to build on our collaboration agreements while reducing our losses. As a result, later…

Continue Reading

WednesdayAug 09, 2017 12:30 pm

NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 9% mid-day following the company’s comments regarding the recent FDA approvals for new drugs for the treatment of acute myeloid leukemia (AML). The company’s drug candidate, Annamycin, is currently being evaluated for the treatment of relapsed or refractory AML. “While these new drugs make valuable incremental improvements in AML therapy, most AML patients will still fail to respond to (or relapse from) initial therapy; therefore, our initial clinical development plan will attempt to address the significant unmet need of patients who relapse from, or are refractory to, initial therapy. We also believe…

Continue Reading

Contact us: 212.418.1217